GLP-1s Like Semaglutide: Less Thyroid Cancer Than Insulin

Among people with type 2 diabetes who received a GLP-1 receptor agonist, there was less correlation between this treatment and thyroid cancer than among people with type 2 diabetes treated with insulin.

Related Keywords

Lebanon ,South Korea ,New York ,United States ,Rachel Pessah ,Dulaglutide Trulicity ,Epic Research ,University Of North Carolina At Chapel Hill ,Novo Nordisk ,While The Epic Research ,North Carolina ,Chapel Hill ,Medscape Medical News ,Rachel Pessah Pollack ,Ambulatory Care ,Lake Success ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Thyroid Disorder ,Malignant Head And Neck Neoplasm ,Thyroid Cancer ,Thyroid Carcinoma ,Ancer Of The Thyroid ,Medullary Thyroid Carcinoma ,Edullary Carcinoma Of The Thyroid ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Thyroid ,Cancer ,Alignant Neoplasia ,Arcinoma ,Receptors ,Healthcare Technology ,Ealth Care T ,